-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LynbKwI09PLuZXpIV89R2LKgPcl+7BpGk5oujczY/fb850w734zc6EbEmevFT8sb bxJ600bB+Bfyl0DrKYpgzA== 0001144204-04-020726.txt : 20041130 0001144204-04-020726.hdr.sgml : 20041130 20041130171434 ACCESSION NUMBER: 0001144204-04-020726 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20041130 ITEM INFORMATION: Other Events FILED AS OF DATE: 20041130 DATE AS OF CHANGE: 20041130 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RITA MEDICAL SYSTEMS INC CENTRAL INDEX KEY: 0001056421 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943199149 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30959 FILM NUMBER: 041175242 BUSINESS ADDRESS: STREET 1: 967 N SHORELINE BLVD CITY: MOUNTAIN VIEW STATE: CA ZIP: 94013 BUSINESS PHONE: 6503858500 MAIL ADDRESS: STREET 1: 967 NORTH SHORELINE BLVD CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 8-K 1 form8k.htm Unassociated Document

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

November 30, 2004
Date of Report
 (Date of earliest event reported)


RITA Medical Systems, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

000-30959

94-3199149

(Commission File Number)

(I.R.S. Employer Identification No.)

   

967 N. Shoreline Blvd.
Mountain View, CA 94043
(Address of principal executive offices, with zip code)

(650) 314-3400
(Registrant's telephone number, including area code)



     
 


Item 8.01. Other Events and Required FD Disclosure.

On November 30, 2004, RITA Medical Systems, Inc., a Delaware corporation (“RITA”), announced the market introduction of its Intelliflow® peristaltic pump for use with the Company’s Starburst ® XLIe family of radiofrequency ablation probes. A copy of RITA’s press release announcing this introduction is attached as Exhibit 99.1 hereto and incorporated by reference herein.



 
     


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
  RITA Medical Systems, Inc.
 
 		  
 		  
 
Date: November 30, 2004 By:   /s/ Donald Stewart
 
Donald Stewart, Chief Financial Officer and
Vice President Finance and Administration

 
 
 
 
 

 
     
 




RITA MEDICAL SYSTEMS, INC.

INDEX TO EXHIBITS


Exhibit Number
Description
  
     
99.1
Press Release of RITA Medical Systems, Inc. dated November 30, 2004.
  


     
 

 
 
 EX-99 2 ex99.htm Unassociated Document
RITA Medical Systems Announces Launch of New IntelliFlow Pump
November 30, 2004 08:55:00 AM ET
 
Peristaltic Pump Features Automated Operation with Starburst(TM) Xli
 
Enhanced Infusion Radiofrequency Ablation Probe and RITA 1500X Generator
 
RITA Medical Systems, Inc. RITA today announced the launch of the IntelliFlow(R) pump for use with the Starburst family of infusion radiofrequency ablation (RFA) probes and model 1500X radiofrequency (RF) generator. The new IntelliFlow pump is part of RITA's radiofrequency ablation system which is a minimally invasive treatment option for cancer patients with unresectable (inoperable) tumors. The FDA-cleared IntelliFlow pump replaces the company's previous original equipment manufacture syringe infusion pump offering and is currently being delivered to customers.
 
Joseph DeVivo, President and CEO of RITA Medical Systems, commented, "We believe the new pump is a significant improvement over prior products offered by the company to support infusion enhanced ablations. We believe the improved ease of use will make it easier for our sales force to convert more of our customers to the Xli-enhanced infusion ablation disposable probe." Mr. DeVivo continued, "We believe that the IntelliFlow pump brings the RITA RFA system to a new level of sophistication unmatched by any other manufacturer."
 
The new IntelliFlow pump was designed by RITA to improve overall ease of use by physicians during infusion enhanced ablation procedures. The company offers saline infusion to physicians who need to make large ablations with reduced treatment times.
 
The Intelliflow system features pre-attached tubing that allows easier set up for infusion procedures. The pump has been integrated with the model 1500X Generator and is designed to require minimal user set-up and little or no operational intervention during infusion enhanced RFA procedures.
 
The "on/off" operation of the Intelliflow system is designed to streamline the automatic operation of saline infusion during procedures and to reduce the need for monitoring of pump function. Automated infusion and power settings are controlled by new proprietary software settings incorporated in the RITA model 1500X RF Generator. The peristaltic pump uses a single flow source from a standard saline bag, which is intended to eliminate the need for multiple syringe infusion sources during procedures.
 
About RITA Medical Systems, Inc.
 
RITA Medical Systems develops manufactures and markets innovative products for cancer patients including radiofrequency ablation (RFA) systems for treating cancerous tumors as well as percutaneous vascular and spinal access systems. The Company's oncology product lines include implantable ports, some of which feature its proprietary Vortex(R) technology; tunneled central venous catheters; safety infusion sets and peripherally inserted central catheters used primarily in cancer treatment protocols. The proprietary RITA system uses radiofrequency energy to heat tissue to a high enough temperature to ablate it or cause cell death. In March 2000, RITA became the first RFA Company to receive specific FDA clearance for unresectable liver lesions in addition to its previous general FDA clearance for the ablation of soft tissue. In October 2002, RITA again became the first company to receive specific FDA clearance, this time, for the palliation of pain associated with metastatic lesions involving bone.
 
The statements in this news release related to the performance of the IntelliFlow pump, its impact on sales of the Starburst system and the technological achievements of the IntelliFlow pump are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Information regarding these risks is included in the Company's filings with the Securities and Exchange Commission.
 
Contact Information: Allen & Caron Inc.
Jill Bertotti, 949-474-4300 (investors) jill@allencaron.com
or SurfMedia Communications
Juliana Minsky, 805-962-3700 (media)
jm@surfmedia.com
or
 
RITA Medical Systems, Inc. Don Stewart, Chief Financial Officer Stephen Pedroff, V.P. Marketing Communications 650-314-3400 dstewart@ritamed.com spedroff@ritamed.com
 
© 2004 BusinessWire
-----END PRIVACY-ENHANCED MESSAGE-----